[Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].
OBJECTIVE
To evaluate the efficacies and toxicity of HAG (HHT + Ara-C + G-CSF) regimen in patients with high-risk myelodysplastic syndromes (MDS).


METHODS
A total of 97 patients with high-risk MDS received HAG regimen as the induction therapy.


RESULTS
The complete remission (CR) rate of all the patients was 52.3% (45/86). The overall response (OR) rate was 66.3% (57/86). The early mortality rate was 9.3% (9/97). There was no significant difference in CR rate and OR rate between the patients aged ≥ 60 and those < 60. The OR rate was 29/34, 9/12 and 6/13 in patients with favorable karyotype, intermediate karyotype and unfavorable karyotype respectively. The OR rate was higher in patients with favorable karyotype than those with unfavorable karyotype (P = 0.038). The major adverse effect was infection.


CONCLUSIONS
HAG regimen provides higher CR rate and OR rate for patients with high-risk MDS.
First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Suzhou 215006, China.
Hong
H
Liu
Guang-sheng
GS
He
De-pei
DP
Wu
Ai-ning
AN
Sun
Zong-hong
ZH
Shao
Si-xuan
SX
Qian
Zhi-jian
ZJ
Xiao
Jun
J
Ma
Shu-ye
SY
Wang
Xiao-ping
XP
Xu
Ting
T
Liu
Jie
J
Jin
Zhi-chao
ZC
Chen
Mei-yun
MY
Fang
Bao-an
BA
Chen
Lan-ping
LP
Xu
Zhi-xiang
ZX
Shen
Chang-geng
CG
Ruan
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D006248:Harringtonines / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D012074:Remission Induction; D055815:Young Adult
D006248:Harringtonines; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor